Phenytoin-induced cleft palate: Evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage

Teratology

Volumn 63, Issue 3, 2001, Pages 152-160

  Azarbayjani, Faranak ^a   Danielsson, Bengt R ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CARDIOTOXICITY; CLEFT PALATE; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; EMBRYOTOXICITY; HYPOXIA; MATERNAL PLASMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REOXYGENATION; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTICONVULSANTS; BRADYCARDIA; CLEFT PALATE; DELAYED RECTIFIER POTASSIUM CHANNELS; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; FETAL HEART; HEART DEFECTS, CONGENITAL; MICE; MICE, INBRED STRAINS; MYOCARDIAL REPERFUSION INJURY; ORAL HEMORRHAGE; PHENYTOIN; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; PREGNANCY;

EID: 0035086561     PISSN: 00403709     EISSN: None     Source Type: Journal    
DOI: 10.1002/tera.1026     Document Type: Article

References (38)

1. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant
2. Pharmacologically induced embryonic dysrhythmia and episodes of hypoxia followed by reoxygenation: A common teratogenic mechanism for antiepileptic drugs?
3. Possible embryofetopathy caused by beta blocker (sotalol) taken throughout the pregnancy
4. Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats
5. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
6. Histopathological and hemodynamic studies supporting hypoxia and vascular disruption as explanation to phenytoin teratogenicity
7. Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations
8. Initiation of phenytoin teratogenesis: Pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation
9. Drug toxicity in embryonic development. II. Cardiovascular active drugs
10. Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to fetal hydantoin syndrome in rats
11. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 2: Human studies
12. Developmental changes in ionic channel activity in the embryonic murine heart
13. Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus
14. Reactive oxygen species in developmental toxicity: Review and hypothesis
15. Role of free radicals in limb teratogenicity of L-NAME (NG-Nitro-L-Arginine Methyl Ester): A new mechanistic model of vascular disruption
16. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades. 1. Animal studies
17. The effect of uterine vascular clamping on the development of rat embryos three to fourteen days old
18. Teratogen update: Fetal hydantoin effects
19. Hypoxia and altered redox status in embryotoxicity
20. Influence of the developmental stage of embryotoxicity following uterine vessel clamping in the rat
21. Fetal pathology in rats following uterine-vessel clamping on day 14 of gestation
22. The effects of phenytoin on rat development: An animal model system for fetal hydantoin syndrome
23. Digit effects produced by prenatal exposure to antiepileptic drugs
24. Abnormalities of the neonatal brain: MR imaging, I: Intracranial hemorrhage
25. + channels by phenytoin in rat neuroblastoma cells
26. Developmental toxicity and pharmacokinetics of oral and intravenous phenytoin in the rat
27. The role of dysrhythmic heart function during cardiovascular teratogenesis in epinephrine-treated chick embryos
28. Developmental toxicity in the pregnant rabbit by the class III antarrhythmic drug sotalol
29. + channels as pharmacological targets: Present and future implications
30. Arrhythmia, heart rate variability, and antiepileptic drugs
31. Phenytoin: Absorption, distribution and excretion
32. Arrhythmia in early pregnancy: A predictor of first-trimester pregnancy loss
33. Effect on in utero exposure to anticonvulsants on craniofacial development and growth
34. Teratogenic potential of almokalant, dofetilide, and d-sotalol: Drugs with potassium channel blocking activity
35. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species
36. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid and alpha-phenyl-N-t-butylnitrone: Implications for bioactivation by prostaglandin synthetase
37. Fetal anticonvulsant syndrome in rats: Dose- and periodresponse relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring
38. + channel, erg